Dr. Adrian Di Bisceglie is a distinguished hepatologist whose career spans academic leadership, clinical research, and biopharmaceutical innovation in liver disease therapeutics. He completed his medical education and internal medicine residency in South Africa before advancing to the National Institutes of Health in Bethesda, where he completed a fellowship in liver diseases and ultimately rose to Chief of the Liver Diseases Section. Joining Saint Louis University in 1994, he served for twenty-five years including twelve years as Chairman of the Department of Internal Medicine, establishing himself as a leading authority in hepatology. Following his academic career, Dr. Di Bisceglie served as Chief Medical Officer for HighTide Therapeutics from 2019 to 2023, transitioning afterward to full-time consulting in the biotechnology sector.
Dr. Di Bisceglie's research has focused extensively on viral hepatitis and hepatocellular carcinoma, securing continuous NIH funding for both clinical and laboratory-based investigations that have significantly advanced the field. His scholarly contributions include over five hundred original articles and book chapters that have shaped contemporary understanding and treatment approaches for liver diseases. At HighTide Therapeutics, he led clinical development for HTD1801, a novel therapeutic candidate demonstrating promising potential for histologic improvement in metabolic dysfunction-associated steatohepatitis and primary sclerosing cholangitis as evidenced by clinical data presented at the American Association for the Study of Liver Diseases. His work bridges fundamental research with practical therapeutic applications, emphasizing metabolic diseases including MASH, diabetes, and hyperlipidemia alongside traditional liver disorder expertise.
As a recognized leader in hepatology, Dr. Di Bisceglie served as President of the American Association for the Study of Liver Diseases in 2014 and received a White House Certificate of Appreciation for his contributions to viral hepatitis prevention and treatment on World Hepatitis Day that same year. His distinguished career has been further honored with the AASLD Distinguished Service Award in 2018 and the Outstanding St. Louis Scientist Award from the Academy of Science of St. Louis. Currently operating as a biotechnology consultant, Dr. Di Bisceglie maintains extensive referral networks throughout the United States and internationally while advising major regulatory agencies including the FDA, NIH, and CDC. His ongoing work continues to influence therapeutic development for liver diseases, leveraging decades of experience to advance clinical solutions for patients with complex hepatic conditions.
